Lincoln Pharmaceuticals Limited
LINCOPH.BO
Bombay Stock Exchange638.15
INR
-12.05
- -
Lincoln Pharmaceuticals Limited
LINCOPH.BO
(Bombay Stock Exchange)
Recent
price
638.15
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Lincoln Pharmaceuticals Limited manufactures, markets, and distributes pharmaceutical formulations in various dosage forms including tablets, capsules, dry syrups, creams, non-sterile and sterile ointments, dry powder injections, ampoules injections, liquid vials, eye drops, and oral liquids. The company offers branded generics and other products across therapeutic areas such as anticold, antibiotics, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids, cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio, central nervous system, respiratory system, and dyslipidemic; specific brands include LENOCARB antacid antiflatulent suspension, PA12 paracetamol SR tablets, TRIXON cefixime oral suspension and tablets, ARH-L Forte arteether and lumefantrine tablets, VIVIAN diclofenac gel, VIVIAN-PLUS aceclofenac and paracetamol tablets, CEPY-200 cefpodoxime tablets, AZILIN-500 azithromycin tablets, and NAMSAFE nimesulide and recemethionine tablets. Lincoln Pharmaceuticals operates manufacturing facilities in Khatraj, Naroda, and Mehsana in Gujarat, India, with products available domestically across India and exported to approximately 60 countries including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia; the company targets healthcare providers, pharmacies, and institutional customers in these markets. Founded in 1979 and headquartered in Ahmedabad, Gujarat, India, Lincoln Pharmaceuticals went public in 1996 with a listing on the Bombay Stock Exchange and added a National Stock Exchange listing in 2015; the company transitioned from a partnership to a public limited entity in 1995 and maintains listings under the ticker LINCOPH.BO. Recent developments include the 2021 acquisition of a plant in Mehsana, Gujarat, for cephalosporin products with commercial production commencing in fiscal 2025, the September 2021 National Company Law Tribunal-approved merger of subsidiary Lincoln Parenteral Limited into the parent company, October 2021 receipt of Australia's Therapeutic Goods Administration certification for its Gujarat plant, and May 2020 attainment of European Union GMP certification for the Khatraj facility; these changes enhance production capacity, product diversification, and regulatory approvals alongside ongoing R&D with over 1,700 product registrations and 700 in the pipeline.